Drug Approval | November 16, 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Fenebrutinib targets cells in the immune system known as B cells and microglia
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Subscribe To Our Newsletter & Stay Updated
